20 results on '"Anderson, Tara C."'
Search Results
2. Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years
3. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged [greater than or equal to] 18 years--United States, July 2022
4. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years--United States, June 2022
5. 1461. The Impact of Universal Varicella Vaccination on Herpes Zoster Incidence in the United States
6. 801. IDSA Featured Oral Abstract: 25 Years of Varicella Vaccination Program in the United States: Health Impact during 1995–2019
7. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50–64 years in the United States
8. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged [greater than or equal to] 19 Years: Recommendations of the Advisory Committee on Immunization Practices--United States, 2022
9. The Impact of Universal Varicella Vaccination on Herpes Zoster Incidence in the United States: Comparison of Birth Cohorts Preceding and Following Varicella Vaccination Program Launch
10. Health and Economic Impact of the United States Varicella Vaccination Program, 1996–2020
11. Monitoring Varicella Vaccine Impact on Varicella Incidence in the United States: Surveillance Challenges and Changing Epidemiology, 1995–2019
12. Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune‐Mediated Inflammatory Diseases in the US
13. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years — United States, July 2022
14. Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine
15. Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults
16. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022
17. Risk of Guillain-Barré syndrome following herpes zoster, United States, 2010–2018
18. Insurance reimbursements for recombinant zoster vaccine in the private sector
19. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
20. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.